Rana Alsabbagh, MD
Endocrinology, Diabetes & Metabolism · Detroit, MINPI 1558356238
Payments from drug & device makers
Across 89 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$266
- Dexcom, Inc.$250
- Novo Nordisk$231
- Regeneron Healthcare Solutions, Inc.$122
- Insulet Corporation$98
- BETA Bionics, Inc.$94
- plus $802 from 24 others
What the payments were for
- Food & beverage$1,85199%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 13 | $266 |
| Dexcom, Inc. | 13 | $250 |
| Novo Nordisk | 12 | $231 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Insulet Corporation | 5 | $98 |
| BETA Bionics, Inc. | 5 | $94 |
| Sanofi-aventis U.S. LLC | 5 | $94 |
| Madrigal Pharmaceuticals | 2 | $70 |
| Amneal Pharmaceuticals LLC | 3 | $67 |
| Verity Pharmaceuticals Inc. | 3 | $67 |
| Amgen | 3 | $52 |
| Radius Health, Inc. | 1 | $50 |
| Lilly USA, LLC | 2 | $41 |
| Tandem Diabetes Care, Inc. | 2 | $36 |
| Corcept Therapeutics | 2 | $36 |
| Mannkind Corporation | 2 | $26 |
| Rhythm Pharmaceuticals, Inc. | 1 | $25 |
| Merck | 2 | $25 |
| AbbVie | 1 | $24 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| Bayer | 1 | $22 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
| Alvogen Inc | 1 | $18 |
| Gilead | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $17 |
| AstraZeneca | 1 | $17 |
| Pfizer | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,863 in reported general payments places this provider in the 45th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 152 | $182,407 |
| MounjaroTirzepatide | 153 | $179,564 |
| JardianceEmpagliflozin | 162 | $129,909 |
| TrulicityDulaglutide | 79 | $124,513 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 137 | $110,499 |
| FarxigaDapagliflozin Propanediol | 75 | $55,298 |
| Tresiba Flextouch U-100Insulin Degludec | 69 | $38,161 |
| Xigduo XrDapaglifloz Propaned/Metformin | 40 | $32,223 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $26,927 |
| SynjardyEmpagliflozin/Metformin Hcl | 18 | $26,270 |
| Novolog FlexpenInsulin Aspart | 91 | $21,977 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $19,957 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 15 | $18,220 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 130 | $16,517 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $15,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $41 | $304,077232 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $14 | $266,679317 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $231 | $207,425184 claims |
| AstraZenecaFarxiga | $17 | $55,29875 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $67 | $5,076430 claims |
| AbbVieSynthroid | $24 | $1,22116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Detroit
- Arti BhanDetroit$298K
- Sudhaker RaoDetroit$164K
- Henry BoneDetroit$140K
- Shobana AthimulamDetroit$14K
- Wael TahaDetroit$12K
- Berhane SeyoumDetroit$11K
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- Lowell SchmeltzFarmington Hills$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.